Molecular Templates Inc (OQ:MTEM)

Sector:  Healthcare Industry:  Biotechnology & Medical Research
 
See Regulatory Filings on SEC
Company Contact
Address: 9301 Amberglen Blvd Ste 100
AUSTIN TX 78729-1153
Tel: N/A
Website: https://mtem.com
IR: See website
<
Key People
Jason S. Kim
President, Chief Financial Officer 		Eric E. Poma
Chief Executive Officer, Chief Scientific Officer, Director 		Kristen Quigley
Chief Operating Officer
Grace Kim
Chief Strategy Officer and Head of Investor Relations 		Maurizio Voi
Chief Medical Officer 		 
Business Overview
Molecular Templates, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted biologic therapeutics. The Company's proprietary drug platform technology, known as engineered toxin bodies (ETBs), leverages the resident biology of a genetically engineered form of Shiga-like Toxin A subunit to create novel therapies with potent and differentiated mechanisms of action for cancer. Its product pipeline includes MT-6402, MT-8421 and MT-0169. MT-6402 is an ETB consisting of a single chain variable fragments (scFv), with affinity for PD-L1, fused to the enzymatically active de-immunized SLTA and a HLA-A*02 class I antigen derived from the human cytomegalovirus (HCMV) pp65 protein. MT-8421, its ETB targeting CTLA-4, along with MT-6402. MT-0169 is designed to destroy CD38+ tumour cells through internalization of CD38 and cell destruction via a novel mechanism of action (enzymatic ribosomal destruction and immunogenic cell death).
Financial Overview
For the fiscal year ended 31 December 2023, Molecular Templates Inc revenues increased from $19.8M to $57.3M. Net loss decreased 91% to $8.1M. Revenues reflect United States segment increase from $17.2M to $52.6M. Lower net loss reflects Research and developm decrease of 40% to $46M (expense), General and administrativ decrease of 25% to $15M (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$24.69 to -$1.80.
Employees: 62 as of Dec 31, 2023
Reporting Currency: U.S. Dollars
Enterprise value: N/A
Annual revenue (TTM): $57.31M as of Dec 31, 2023
EBITDA (TTM): -$3.75M as of Dec 31, 2023
Net annual income (TTM): -$8.12M as of Dec 31, 2023
Free cash flow (TTM): -$42.02M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 6,583,880 as of Apr 2, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.

Learn More